Non Small Cell Lung Cancer
Conditions
Keywords
NSCLC
Brief summary
This multi-center, open label phase II clinical study is performed in patients with locally advanced or metastatic EGFR wild-type ALK wild-type non-small cell lung cancer progressed on prior anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with chemotherapy in patients.
Interventions
DRUGSI-B001
SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
DRUGAP or TP
AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.
DRUGDocetaxel
Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.
Sponsors
Sichuan Baili Pharmaceutical Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Voluntarily sign informed consent forms and follow program requirements； 2. Male or female; 3. Age: ≥ 18 years; 4. Expected survival time ≥ 3 months; 5. Patients with locally advanced or metastatic EGFR wild-type ALK wild-type lung cancer, disease progression or intolerance after first-line treatment with anti-PD-1/PD-L1 antibody, disease progression or intolerance after first-line treatment with anti-PD-1/PD-L1 antibody and platinum-based chemotherapy, or progression or intolerance after first-line treatment with anti-PD-1/PD-L1 monoclonal antibody; 6. The subject agrees to provide archival tumor tissue samples or fresh tissue samples of the primary tumor or metastases within 6 months; if the subject is unable to provide tumor tissue samples and the subject is unable to provide the gene sequencing report, the subject shall agree to complete the ctDNA EGFR detection during the screening period, and can be assessed by the investigator if other inclusion criteria are met; 7. Must have at least one measurable lesion as defined by RECISTv1.1; 8. Performance status score ECOG0 or 1; 9. Toxicities from prior anticancer therapy have recovered to grade ≤ 2 as defined by NCI-CTCAEv5.0 (except alopecia); 10. No severe cardiac dysfunction, left ventricular score ≥ 50%; 11. The level of organ function must meet the following criteria: 1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet count ≥ 80 × 109/L, hemoglobin ≥ 90 g/L; 2. Liver function: TBIL ≤ 1.5ULN (total bilirubin ≤ 3ULN for subjects with Gilbert's syndrome, liver cancer or liver metastases); AST and ALT ≤ 2.5ULN for subjects without liver metastases; AST and ALT ≤ 5.0ULN for subjects with liver metastases; 3. Renal function: creatinine (Cr) ≤ 1.5ULN, or creatinine clearance (Ccr) ≥ 50 mL/min (according to CockcroftandGault formula). 12. Coagulation function: international normalized ratio (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (APTT) ≤ 1.5ULN; 13. Urine protein ≤ 2 + (measured by dipstick) or \< 1000 mg/24 h (urine); 14. Premenopausal women of childbearing potential must have a negative serum or urine pregnancy test 7 before starting treatment and must be non-lactating; all patients (male or female) should take adequate barrier contraception measures throughout the treatment cycle and 6 months after the end of treatment.
Exclusion criteria
1. Patients with past use of docetaxel； 2. Prior to signing the informed consent, the gene sequencing or ctDNA testing report of the previous tissue samples indicated the presence of MET 14 exon jump positive, ROS1 rearrangement positive, BRAF V600E mutation positive, NTRK fusion positive, RET rearrangement positive, HER2 mutation positive, HER2 amplification positive, Patients with KRAS G12C mutation positive； 3. Chemotherapy, biotherapy, immunotherapy, radical radiotherapy, and major surgery were used within 4 weeks before the first administration; palliative radiotherapy, targeted therapy (including small-molecule tyrosine kinase inhibitors) and other antitumor therapy were used within 2 weeks; 4. Screening the history of severe heart disease within the first six months, such as: symptomatic congestive heart failure (CHF) ≥2 (CTCAE v5.0) history, New York Heart Society (NYHA) ≥2 heart failure, acute coronary syndrome, etc.; 5. Prolonged QT interval (QTc \> 450 msec in men or 470 msec in women), complete left bundle branch block, and Degree III atrioventricular block; 6. Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, except for type I diabetes, hypothyroidism controllable by replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis); 7. Other malignancies diagnosed within 5 years prior to first dose,Exceptions include: radical basal cell carcinoma of the skin, scaly cell carcinoma of the skin, and/or radical resection of carcinoma in situ; 8. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 100 mmHg); 9. Pulmonary disease defined as ≥ grade 3 according to CTCAEv5.0, including resting dyspnea, or requiring continuous oxygen therapy, or patients with a history of interstitial lung disease (ILD); 10. Symptoms of active central nervous system metastases.However, patients with stable parenchymal metastases can be stable, and whether it is stable or not is judged by the investigator; 11. Patients with a history of hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies or hypersensitivity to SI-B001 or any of the excipient components of Osimertinib; 12. History of autologous or allogeneic stem cell transplantation; 13. In previous anthracycline (neo) adjuvant therapy, the cumulative dose of anthracycline was \> 360 mg/m2; 14. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number \> 104) or hepatitis C virus (HCV) infection; 15. Active infection requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.; 16. Received other unmarketed clinical study drugs or treatments within 4 weeks prior to study participation; 17. Other conditions for trial participation were not considered by the investigator to be appropriate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | Up to approximately 24 months | Objective Response Rate |
| Optimal combination dose (only IIa) | Up to approximately 24 months | Optimal combination dose of SI-B001 with chemotherapy (only IIa) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DCR | Up to approximately 24 months | Disease Control Rate |
| DOR | Up to approximately 24 months | Duration of Response |
| TEAE | Up to approximately 24 months | Treatment Emergent Adverse Events |
| OS | Up to approximately 24 months | Overall Survival |
| Tmax | Up to approximately 24 months | Time to maximum serum concentration |
| Ctrough | Up to approximately 24 months | Minimum serum concentration |
| ADA | Up to approximately 24 months | anti-SI-B001 antibody |
| Cmax | Up to approximately 24 months | Maximum serum concentration |
| PFS | Up to approximately 24 months | Progression Free Survival |
Countries
China
Outcome results
None listed